Binding Site Introduces New Affinity-Purified Polyclonal Antibodies to Human IgA and IgM
Both of these affinity-purified antibodies demonstrate high degrees of specificity and display minimal species cross-reactivity with bovine, mouse, and rat serum proteins
San Diego, CA — Binding Site’s Immunologicals Group is pleased to announce the addition of two new sheep anti-human IgA and IgM antibodies to its broad offering of products for in-vitro diagnostic (IVD) manufacturing and research applications. Both of these unconjugated, polyclonal antibodies have been expressly designed for use as an integral component within a variety of test procedures, especially ELISAs and Western Blots. As such, researchers involved in the biopharmaceutical, clinical, and life science fields, as well as select IVD manufacturers, will find the availability of these products particularly useful in their efforts.
Both of these affinity-purified antibodies demonstrate high degrees of specificity and display minimal species cross-reactivity with bovine, mouse, and rat serum proteins. In addition, the antibodies also feature exceptional lot-to-lot consistencies and offer extended shelf life stability claims. Both of are available in compact, standard-sized vials of 1.0mg; with larger bulk configurations also being available.
Binding Site’s Immunologicals Group serves the in-vitro diagnostic (IVD) manufacturing and biopharmaceutical | clinical | life-science | medical research markets with a comprehensive line of innovative products. For additional information, contact The Binding Site, Inc. at 6730 Mesa Ridge Road, San Diego, CA 92121 USA. Phone: 800-633-4484; FAX: 858-453-9189; Email: info@thebindingsite.com. Please visit our website at www.immunologicals.com.